Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03383198 · ClinicalTrials.gov registry record · Phase 4
Pectoralis (II) Block With Liposomal Bupivacaine vs Bupivacaine for Breast Surgery
A Phase 4 study, sponsored by Prisma Health-Upstate.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03383198 is a Phase 4 study that was terminated before completion, run by Prisma Health-Upstate. The registered enrollment target is 5 participants.
The verdict
NCT03383198, a Phase 4 study, was terminated before completion, sponsored by Prisma Health-Upstate.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a randomized controlled pilot study evaluating length of pain control with either liposomal bupivacaine or with bupivacaine plus decadron after PEC II injection in patients having bilateral mastectomies with immediate reconstruction.
Interventions
- DRUG Liposomal bupivacaine right injection
- DRUG Liposomal bupivacaine left injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03383198
The ClinicalTrials.gov registry entry for NCT03383198 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal bupivacaine right injection is the first listed.
NCT03383198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03383198 about?
NCT03383198 is a clinical study titled "Pectoralis (II) Block With Liposomal Bupivacaine vs Bupivacaine for Breast Surgery". This is a randomized controlled pilot study evaluating length of pain control with either liposomal bupivacaine or with bupivacaine plus decadron after PEC II injection in patients having bilateral mastectomies with immediate reconstruction.
What is the current status of trial NCT03383198?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2017-12-01. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03383198?
The interventions under investigation include: Liposomal bupivacaine right injection (DRUG), Liposomal bupivacaine left injection (DRUG).
Who is sponsoring clinical trial NCT03383198?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.